Literature DB >> 15085488

An update on the molecular genetics of hepatocellular carcinoma.

Arief Suriawinata1, Ruliang Xu.   

Abstract

Hepatocellular carcinoma (HCC) is associated with multiple risk factors and is believed to arise from preneoplastic lesions, usually in the background of cirrhosis. Extensive studies on HCC and its precursors have demonstrated complex and heterogeneous genetic or chromosomal abnormalities along the way from preneoplastic lesions to HCCs. These genetic abnormalities include loss of heterozygosity, microsatellite instability, gene alterations, and aberrant global gene expression profiles. Although some genetic alterations involving the p53 family, Rb family, and Wnt pathways are particularly important in the development of HCCs, the molecular pathogenesis of HCC differs with etiology in some extent. Recent studies using DNA microarray technique have identified some unique gene expression profiles in hepatitis B virus (HBV)- and hepatitis C virus (HCV)-associated HCCs. Gene expression profiling also allows people to distinguish HCCs from normal tissue or preneoplastic lesions and to evaluate metastatic or recurrent potentials. These unique genes or gene products associated with malignant transformation and recurrent or metastatic potentials may serve as molecular markers for early diagnosis, prediction of prognosis, and responsiveness to therapy. To date, information that has accumulated for the past several decades is still incomplete, and we still are faced with a great challenge in deciphering the molecular mechanisms of HCCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085488     DOI: 10.1055/s-2004-823102

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  34 in total

Review 1.  [Molecular therapy in gastroenterology and hepatology].

Authors:  J Wedemeyer; N P Malek; M P Manns; M J Bahr
Journal:  Internist (Berl)       Date:  2005-08       Impact factor: 0.743

Review 2.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

3.  Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

4.  A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection.

Authors:  Saadettin Kilickap; Ayse Kars; Erhan Hamaloglu; Halis Simsek
Journal:  Med Oncol       Date:  2009-08-18       Impact factor: 3.064

Review 5.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Wilson disease and hepatocellular carcinoma.

Authors:  Ruliang Xu; Cristina H Hajdu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-06

7.  Genetic alterations of hepatocellular carcinoma by random amplified polymorphic DNA analysis and cloning sequencing of tumor differential DNA fragment.

Authors:  Zhi-Hong Xian; Wen-Ming Cong; Shu-Hui Zhang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

8.  Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival.

Authors:  Hsi-Huang Tseng; Yaw-Huei Hwang; Kun-Tu Yeh; Jan-Gowth Chang; Yao-Li Chen; Hsin-Su Yu
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-29       Impact factor: 4.553

9.  Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes.

Authors:  James O'Beirne; Farzin Farzaneh; Phillip M Harrison
Journal:  J Exp Clin Cancer Res       Date:  2010-05-13

10.  Evolving therapies in the treatment of hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.